

CHARACTERISTICS AND POTENTIAL BENEFITS OF THE RANIBIZUMAB PRE-FILLED SYRINGE

Purpose:

Prefilled syringes (PFS) are one of the fastest growing classes of drug-delivery systems; in addition to being convenient to use, they also may have the potential to reduce the risk of contamination. For intravitreal applications, the elimination of several steps during aseptic preparation may reduce the risk of potential iatrogenic eye infections that may result from suboptimal drug/device handling.

Methods: Characteristics, development process, and potential benefits of ranibizumab PFS are described.

Results: The design features and functionality of ranibizumab PFS are as follows: 1) LUER lock closure system holding the needle tightly and enables needle choice; 2) small syringe barrel (0.5 mL) with low void volume (fill volume: 0.165 mL); 3) unambiguous dose mark that facilitates high dose accuracy; 4) non-reactive borosilicate glass that provides storage stability; 5) non-retractable stopper to prevent inadvertent drawing of non-sterile air and to minimize the potential for sterility-related ocular adverse events; 6) specially designed blister packaging that prevents the contamination of sterile outer syringe surface. A baked 'silicone' process is used for the development of minimally-siliconized PFS. The barrel's inner surface is spray-coated with silicon oil-in-water emulsion and subsequently heat fixed. There were no relevant differences observed in product stability between ranibizumab vials and the PFS.

Conclusions: The ranibizumab PFS aims to improve physician convenience and efficiency of ranibizumab administration in clinical practice with the potential to reduce risk of eye infection and saving time for patients and physicians. Real time clinical practice data will help demonstrate the advantages of ranibizumab PFS.